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Abstract
Renin‐angiotensin‐aldosterone	 system	 inhibitors	 (RAASi)	 are	 recommended	 for	
chronic	 kidney	 disease	 (CKD)	 patients.	 In	 this	 study,	we	 describe	 RAASi	 prescrip‐
tion	patterns	in	the	Chronic	Kidney	Disease	Outcomes	and	Practice	Patterns	Study	
(CKDopps)	in	Brazil,	Germany,	France,	and	the	United	States	(US).	5870	patients	(mean	
age	66‐72	years;	congestive	heart	failure	[CHF]	 in	11%‐19%;	diabetes	in	43%‐54%;	
serum	potassium	≥5	in	20%‐35%)	were	included.	RAASi	prescription	was	more	com‐
mon	 in	Germany	 (80%)	 and	France	 (77%)	 than	Brazil	 (66%)	 and	 the	United	 States	  
(52%),	where	the	prevalence	of	prescription	decreases	particularly	 in	patients	with	
CKD	 stage	 5.	 In	 the	multivariable	 regression	model,	 RAASi	 prescription	was	 least	
common	in	the	United	States	and	more	common	in	patients	who	were	younger,	had	
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diabetes,	hypertension,	or	less	advanced	CKD.	In	conclusion,	RAASi	prescription	pat‐
terns	vary	by	country,	and	by	demographic	and	clinical	characteristics.	RAASi	appear	
to	be	underused,	even	among	patients	with	strong	class‐specific	recommendations.	
Although	the	reasons	for	this	variation	could	not	be	fully	identified	in	this	cross‐sec‐
tional	observation,	our	data	indicate	that	the	risk	of	hyperkalemia	may	contribute	to	
the	underuse	of	this	class	of	agents	in	moderate	to	advanced	CKD.
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1  | INTRODUC TION
Given	the	high	prevalence	of	diabetes,	proteinuria,	and	congestive	heart	
failure	 (CHF)	 in	 the	 chronic	 kidney	 disease	 (CKD)	 population,	 clinical	
practice	 guidelines	 support	 the	 prescription	 of	 renin‐angiotensin‐al‐
dosterone	system	inhibitors	 (RAASi)	 for	most	patients	with	CKD	as	a	
strategy	to	limit	CKD	progression	and	manage	cardiac	comorbidities.1‐3 
The	prescription	pattern	of	RAASi	in	patients	with	CKD	is	still	unknown,	
particularly	in	general	nephrology	practice	in	a	“real‐world	setting.”
Decreasing	renal	function	and	the	associated	interference	with	po‐
tassium	(K)	excretion	is	a	major	cause	for	potassium	elevation.	In	clini‐
cal	practice,	however,	the	development	of	hyperkalemia	is	usually	the	
result	of	a	combination	of	factors	superimposed	on	renal	dysfunction,	
such	as	diabetes	mellitus	with	high	glucose	 levels	or	hyporeninemic	
hypoaldosteronism	and	advanced	stages	of	heart	failure	with	accom‐
panying	reductions	in	renal	perfusion.4	Additionally,	serum	potassium	
is	 influenced	 by	 the	 use	 of	medications	with	 hyperkalemic	 effects,	
such	as	angiotensin‐converting	enzyme	inhibitors	 (ACEIs),	angioten‐
sin	receptor	blockers	(ARBs),	mineralocorticoid‐receptor‐antagonists	
(MRA),	and	medications	that	can	lead	a	reduction	in	serum	potassium	
level,	such	as	diuretics,	bicarbonate,	and	potassium	binders.5
As	such,	motivating	hypotheses	for	this	analysis	are	that	the	pre‐
scription	of	RAASi	 is	 relatively	 low	 in	 some	patients	with	CKD,	 in	
contrast	 to	 practice	 guidelines	 and	 even	 in	 real‐life	 studies	 based	
in	 academic	 practices.	 The	main	 objectives	 of	 this	 study	 were	 as	
follows:	 (a)	 to	 describe	 RAASi	 use	 in	 the	 Chronic	 Kidney	Disease	
Outcomes	 and	 Practice	 Patterns	 Study	 (CKDopps)	 overall	 and	 by	
country;	by	patient	characteristics,	including	CKD	stage,	level	of	pro‐
teinuria,	serum	potassium	level,	diabetic/heart	failure	status;	by	use	
of	other	medications	such	as	diuretics;	and	by	clinic‐level	variation;	
and	(b)	to	explore	patient	characteristics	associated	with	RAASi	use.
2  | METHODS
2.1 | Study design and analytic cohort selection
We	conducted	a	cross‐sectional	analysis	of	data	from	the	CKDopps.	
CKDopps	 is	 an	 ongoing	 international	 prospective	 cohort	 study	
of	 non‐dialysis	 patients	 with	 estimated	 glomerular	 filtration	 rate	
(eGFR)	<60	mL/min/1.73	m2.	Participants	were	sequentially	or	ran‐
domly	selected	from	national	samples	of	nephrologist‐run	CKD	clin‐
ics	in	Brazil,	France,	Germany,	Japan,	and	the	United	States	(US).	The	
CKDopps	 study	 design	 and	 protocol	 details	 have	 been	 published	
previously.6	 The	 ratio	 of	 enrolled	 patients	 with	 eGFR	 <	 30	 mL/
min/1.73 m2	 compared	with	 patients	with	 eGFR	of	 30‐	 <	 60	mL/
min/1.73 m2	was	2:1	in	Brazil	and	US	clinics;	3:1	in	German	clinics;	
and	1:1	in	French	clinics.	At	study	enrollment,	patient	demograph‐
ics	and	comorbidities	are	captured,	as	well	as	laboratory	data	up	to	
6	months	prior	 to	enrollment,	 if	available.	Routine	 laboratory	data	
are	 collected	during	 longitudinal	 follow‐up	based	upon	how	often	
these	data	are	measured	for	clinical	care,	up	to	a	monthly	frequency.	
Medication‐related	data	are	also	collected	longitudinally	throughout	
study	follow‐up.	In	Brazil,	France,	and	the	United	States,	clinical	data	
are	captured	via	medical	record	abstraction,	while	in	Germany,	data	
are	captured	from	electronic	health	records	(EHRs)	after	data	review	
performed	by	a	study	coordinator	to	assess	data	quality.	The	study	
was	conducted	with	adherence	 to	 the	Declaration	of	Helsinki	and	
received	research	ethics	board	approval	(study	number:	14004‐05).	
All	patients	provided	written	informed	consent	before	enrollment.
These	analyses	utilized	data	 from	Brazil,	France,	Germany,	and	
the	United	States.	Data	from	Japan	were	not	yet	available	at	the	time	
of	analysis.	 In	 the	 four	participating	countries,	 a	 total	of	7590	pa‐
tients	from	national	samples	of	127	nephrology	clinics	had	enrolled	
as	of	September	3,	2018;	430	patients	were	excluded	because	the	
absence	of	baseline	demographic	characteristics	and	medical	history	
data;	492	patients	were	excluded	from	the	current	analyses	because	
of	 no	 serum	potassium	data;	 and	 an	 additional	 798	patients	were	
excluded	for	no	medication	data,	yielding	a	final	analytic	cohort	of	
5870	patients.
2.2 | Data and statistical analyses
Baseline	 cross‐sectional	 data	 were	 used	 for	 the	 analyses.	
Albuminuria	was	defined	and	classified	 into	 three	categories	 ac‐
cording	to	Kidney	Disease:	 Improving	Global	Outcomes	 (KDIGO)	
2012	 guidelines—normal	 or	 mildly	 increased	 (A1,	 <30	 mg/g),	
F I G U R E  1  Study	flowchart
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moderately	increased	(A2,	30‐300	mg/g),	and	severely	increased	
(A3,	>300	mg/g),	using	spot	or	24‐hour	urine	albumin	or	protein‐
to‐creatinine	 ratio.	 Comorbidity	 data	 were	 supplemented	 with	
medication	use	and	 laboratories	 in	France	 (eg,	HbA1c	and	blood	
glucose	 for	 diabetes)	 and	 determined	 based	 on	 International	
Classification	 of	 Diseases	 (ICD‐10)	 codes	 in	 Germany.	 Standard	
descriptive	 statistics	 (means	 and	 standard	 deviations	 [SDs]	 or	
medians	and	 interquartile	 ranges	 [IQRs]	 for	continuous	variables	
and	frequencies	for	categorical	variables)	were	used	to	report	co‐
hort	characteristics	by	RAASi	use	at	CKDopps	entry	and	country.	
Serum	 potassium	 and	 RAASi	 practice	 patterns	 were	 compared	
across	CKD	stages	and	countries,	as	well	as	by	clinical	 indication	
for	RAASi	use.	To	identify	patient	characteristics	and	other	treat‐
ments	associated	with	RAASi	use,	multivariable	modified	Poisson	
regression	 sequential	 models	 with	 sandwich	 variance	 estimator	
were	used	to	estimate	RAASi	prevalence	ratios	(PR).	All	statistical	
analyses	were	conducted	using	SAS,	version	9.4	(SAS	Institute	Inc).
3  | RESULTS
After	the	application	of	inclusion	and	exclusion	criteria,	5870	partici‐
pants	were	included	in	the	analysis	(Figure	1).	Patient	characteristics	
by	country	and	RAASi	prescription	status	are	displayed	in	Table	1.	
F I G U R E  2  Potassium	levels	by	
CKD	stage	and	country.	*Includes	ACEi	
(angiotensin‐converting	enzyme	inhibitor)	
or	ARB	(angiotensin	II	receptor	blocker),	
direct	renin	inhibitors,	and	aldosterone	
receptor	antagonists
F I G U R E  3  Prevalence	of	RAASi*	
prescription	by	CKD	stage	and	country.	
*Includes	ACEi	(angiotensin‐converting	
enzyme	inhibitor)	or	ARB	(angiotensin	II	
receptor	blocker),	direct	renin	inhibitors,	
and	aldosterone	receptor	antagonists
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F I G U R E  4  Prevalence	of	RAASi*	
prescription,	by	indication	for	use	and	
country.	A,	by	level	of	albuminuria/
proteinuria†.	*Includes	ACEi	(angiotensin‐
converting	enzyme	inhibitor)	or	ARB	
(angiotensin	II	receptor	blocker),	direct	
renin	inhibitors,	and	aldosterone	receptor	
antagonists.	†KDIGO	2012	guidelines:	
normal	or	mildly	increased	(A1,	<30	mg/g);	
moderately	increased	(A2,	30‐300	mg/g);	
severely	increased	(A3,	>300	mg/g).	‡%	
Missing	of	albuminuria	data	ranges	from	
11%	in	France	to	44%	in	Germany.	B,	by	
diabetes	status	and	by	albuminuria	status.	
*Includes	ACEi	(angiotensin‐converting	
enzyme	inhibitor)	or	ARB	(angiotensin	II	
receptor	blocker),	direct	renin	inhibitors,	
and	aldosterone	receptor	antagonists.	
C,	by	congestive	heart	failure	status	and	
by	albuminuria	status.	*Includes	ACEi	
(angiotensin‐converting	enzyme	inhibitor)	
or	ARB	(angiotensin	II	receptor	blocker),	
direct	renin	inhibitors,	and	aldosterone	
receptor	antagonists
(a)
(b)
(c)
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Mean	 age	was	 66	 years	 in	 Brazil,	 67	 years	 in	 France,	 72	 years	 in	
Germany,	and	68	years	 in	 the	United	States.	The	percentage	with	
CKD	Stage	 4	was	 53%	 in	Brazil,	 42%	 in	 France,	 74%	 in	Germany,	
and	 57%	 in	 the	United	 States.	 The	most	 frequently	 observed	 co‐
morbidities	were	hypertension	 (92%	 in	Brazil,	91%	 in	France,	86%	
in	 Germany,	 and	 93%	 in	 the	 United	 States)	 followed	 by	 diabetes	
(46%	in	Brazil,	43%	in	France	and	in	Germany,	and	54%	in	the	United	
States).	The	proportion	of	patients	with	CHF	was	19%	in	Brazil,	13%	
in	France,	11%	in	Germany,	and	16%	in	the	United	States.	Among	pa‐
tients	with	albuminuria	measurements,	49%	in	Brazil,	73%	in	France,	
66%	in	Germany,	and	70%	in	the	United	States	had	moderately	to	
severely	increased	albuminuria.
The	mean	serum	potassium	level	was	higher	in	Brazil	(4.75	mEq/L)	
than	in	France	(4.54	mEq/L),	Germany	(4.60	mEq/L),	and	the	United	
States	 (4.50	mEq/L)	 (Table	1).	 Serum	potassium	 levels,	 by	 country	
and	by	CKD	stage,	are	presented	in	Figure	2.	Serum	potassium	lev‐
els	were	higher	 in	more	advanced	stages	of	CKD.	RAASi	prescrip‐
tion	was	more	 common	 in	Germany	 (80%)	 and	France	 (77%)	 than	
Brazil	 (66%)	and	the	United	States	 (52%)	 (Table	1).	The	prevalence	
of	RAASi	prescriptions,	by	country	and	by	CKD	stage,	 is	shown	in	
Figure	3.	RAASi	prescription	was	less	common	with	increasing	CKD	
stage	 in	Brazil	and	the	United	States,	but	no	noticeable	difference	
by	CKD	 stage	was	 observed	 in	 France	 and	Germany.	 The	 type	of	
RAASi	prescribed	varied	by	countries,	with	ARBs	more	 frequently	
prescribed	 in	 Brazil	 and	 France	 than	 in	 Germany	 and	 the	 United	
States.	 The	median	 prevalence	 of	 RAASi	 prescription	within	 each	
clinic	ranged	from	68%	in	Brazil,	77%	in	France,	81%	in	Germany,	and	
52%	in	the	United	States	(Figure	S1).	The	between‐clinic	variability	
in	prevalence	of	RAASi	prescription	within	each	country	was	lower	
in	Brazil	(IQR:	7%)	compared	with	France	(IQR:	14%),	Germany	(IQR:	
14%),	and	the	United	States	(IQR:	13%).
Patients	prescribed	RAASi	were	younger	in	all	countries	except	
Germany,	had	less	advanced	CKD,	had	greater	prevalence	of	diabe‐
tes	and	hypertension,	had	higher	serum	potassium	level,	and	more	
frequently	were	prescribed	diuretics	(Table	1).	According	to	the	pa‐
tient	self‐administered	questionnaire,	more	than	50%	of	patients	re‐
ported	that	the	health	care	team	did	not	recommend	any	change	in	
potassium	intake	for	the	last	3	months	prior	to	enrollment,	despite	
the	prescription	of	RAASi.	The	prevalence	of	RAASi	prescription	by	
indication	for	use	is	shown	in	Figure	4.	RAASi	prescription	was	more	
frequent	in	patients	with	albuminuria	in	Brazil	and	France,	but	similar	
despite	the	presence	of	albuminuria	in	other	countries	(Figure	4A).	
The	prevalence	of	RAASi	prescription	was	higher	among	those	with	
diabetes	than	those	without	diabetes,	despite	the	presence	of	albu‐
minuria	in	France	and	the	United	States,	but	there	was	no	noticeable	
difference	in	other	countries	(Figure	4B).	Patients	with	CHF	and	al‐
buminuria	 had	 higher	 prevalence	 of	 RAASi	 prescriptions	 in	Brazil,	
but	this	was	not	observed	in	other	countries	(Figure	4C).
In	the	multivariable	regression	model	(Table	2),	RAASi	prescrip‐
tion	was	least	common	in	the	United	States,	and	more	common	in	pa‐
tients	who	were	younger,	or	had	diabetes	or	hypertension.	However,	
the	presence	of	other	comorbidities,	including	CHF,	demonstrated	no	
difference	in	RAASi	prescription.	Compared	with	the	patients	with	
CKD	Stage	3b,	the	adjusted	prevalence	of	RAASi	prescription	was	
similar	for	CKD	Stages	3a	and	4,	but	about	30%	lower	for	patients	
with	CKD	Stage	5	 (PR	=	0.70;	95%	CI	=	0.61,	0.80).	Patients	with	
hypertension	(52%	higher)	or	diabetes	(8%	higher)	were	more	likely	
to	be	prescribed	RAASi	than	patients	without	those	comorbidities.
Model 1 Model 2 Model 3
Country	(vs	US)
Brazil 1.27	(1.09,1.49) 1.29	(1.12,1.49) 1.29	(1.12,1.48)
France 1.49	(1.32,1.68) 1.41	(1.25,1.58) 1.44	(1.29,1.62)
Germany 1.53	(1.36,1.73) 1.48	(1.31,1.66) 1.51	(1.34,1.69)
Demographics
Age,	per	10	y 0.97	(0.96,0.99) 0.96	(0.94,0.97)
Female	sex	(vs	male) 0.96	(0.93,0.99) 0.96	(0.93,0.99)
CKD	stage	(vs	stage	3b)
3a 1.00	(0.94,1.06) 1.00	(0.95,1.05)
4 0.96	(0.92,1.00) 0.96	(0.92,1.00)
5 0.70	(0.61,0.81) 0.70	(0.61,0.80)
Comorbidities	(yes	vs	no)
Coronary	artery	disease 0.99	(0.96,1.02)
Congestive	heart	failure 0.94	(0.89,1.00)
Diabetes 1.08	(1.04,1.12)
Hypertension 1.52	(1.38,1.68)
Abbreviations:	ACEi,	angiotensin‐converting	enzyme	inhibitors;	ARB,	angiotensin	receptor	blocker;	
CKD,	chronic	kidney	disease;	RAASi,	renin‐angiotensin‐aldosterone	system	inhibitors;	US,	United	
States.
aIncludes	ACEi,	ARB,	direct	renin	inhibitors,	and	aldosterone	receptor	antagonists.	
TA B L E  2  Prevalence	ratios	for	RAASia 
prescription	from	modified	Poisson	
models	with	different	levels	of	adjustment
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4  | DISCUSSION
Current	guidelines	support	 the	prescription	of	RAASi	 for	CKD	pa‐
tients,	particularly	those	with	diabetes,	proteinuria,	or	heart	failure.	
The	results	of	this	multinational	study	indicate	that	RAASi	are	gen‐
erally	 underused	 in	 advanced	 CKD,	 most	 strikingly	 in	 the	 United	
States.	RAASi	prescriptions	were	more	frequent	with	the	presence	
of	diabetes	and	hypertension	comorbidities	and	less	frequent	with	
renal	dysfunction,	particularly	at	advanced	CKD	stages.
There	were	 significant	differences	 in	RAASi	prescription	pat‐
terns	 across	 the	 different	 countries	 captured	 in	 this	 study,	 with	
a	 consistently	higher	RAASi	prescription	 in	France	and	Germany	
compared	with	the	United	States	and	Brazil;	these	differences	were	
particularly	visible	in	more	advanced	stages	of	CKD.	These	findings	
contrast	with	the	analysis	of	the	Ramipril	Efficacy	in	Nephropathy	
(REIN)	trial,	which	shows	that	the	benefit	of	RAASi	in	reducing	the	
progression	of	CKD	is	not	dependent	of	the	degree	of	kidney	dys‐
function	at	the	moment	when	treatment	is	introduced.7	In	contrast	
to	 current	 recommendations,	 RAASi	 was	 prescribed	 in	 a	 limited	
number	of	individuals	of	this	high‐risk	population,	especially	in	the	
United	States	and	Brazil,	even	among	patients	with	strong	class‐
specific	 recommendations,	 including	 albuminuria,	 diabetes,	 or	
heart	failure.1‐3.	In	the	present	study,	patients	prescribed	a	RAASi	
were	younger,	had	 less	advanced	CKD,	and	had	more	comorbidi‐
ties.	No	major	differences	were	observed	 in	 laboratory	values	of	
patients	prescribed	RAASi	compared	with	those	who	were	not.
Previous	 studies	 have	 shown	 a	 variation	 in	 RAASi	 prescription	
patterns,	depending	on	the	setting	of	patient	care.	A	subgroup	with	
eGFR	<	60	mL/min	enrolled	in	the	Chronic	Renal	Insufficiency	Cohort	
(CRIC)	study	showed	that	patients	with	prior	contact	with	a	nephrolo‐
gist	were	more	likely	(75%)	to	receive	ACEi/ARB	compared	with	those	
followed	up	in	primary	care	(67%).	It	is	noticeable	that	the	prescrip‐
tion	pattern	of	ACE/ARBs	in	this	American	academic	cohort8	shows	
distinct	results	compared	with	the	general	nephrology	practice	in	a	
broader	sample	captured	in	the	present	study,	which	is	comparable	
with	the	findings	of	the	most	recent	US	Renal	Data	System	report.9
While	hyperkalemia	 is	only	present	 in	2%	of	patients	 treated	
with	 RAASi	 due	 to	 hypertension	with	 apparently	 normal	 kidney	
function,	 the	 incidence	 of	 hyperkalemia	 in	 patients	with	CKD	 is	
substantially	 higher.10	 In	 the	 Irbesartan	 Diabetic	 Nephropathy	
Trial	 (IDNT)	 of	 patients	 with	 type	 2	 diabetes	 and	 diabetic	 ne‐
phropathy,	the	incidence	of	hyperkalemia,	as	defined	by	a	serum	
potassium	>6.0	mmol/L,	was	18.6%.11	Previous	studies	identified	
CKD	as	an	important	risk	factor	for	hyperkalemia.	Interestingly,	in	
patients	with	eGFR	<	30	mL/min,	the	use	of	RAAS	inhibitors	was	
associated	with	an	 increased	risk	for	hyperkalemia,	and	diuretics	
with	an	increased	risk	for	hypokalemia.12	In	our	study,	hyperkale‐
mia	varied	across	different	countries	and	particularly	CKD	stages.	
As	 expected,	mean	 serum	 potassium	 increases	 as	GFR	 declines,	
as	does	the	prevalence	of	hyperkalemia,	as	defined	by	serum	po‐
tassium	higher	than	5.5	mEq/L.	Hyperkalemia	was	more	common	
in	Brazil	 than	 the	United	States	 and	Germany;	 several	measures	
used	 to	 control	 hyperkalemia,	 such	 as	 prescription	 of	 diuretics,	
potassium‐binding	 resins,	 and	 bicarbonate	 supplementation,	 as	
well	 as	 dietary	 advice	 varied	 across	 countries,	were	 uncommon.	
This	finding	contrasts	with	the	importance	of	RAASi	use	and	the	
high	risk	of	hyperkalemia	in	this	study’s	patient	population.
Among	medications	studied,	only	the	concomitant	prescription	
of	 diuretics	was	 associated	with	 higher	 prevalence	 of	 RAASi	 pre‐
scription.	 Diuretics	 are	 commonly	 prescribed	 in	 the	 CKD	 popula‐
tion,	 particularly	 in	moderate	 to	 advanced	CKD	 for	 the	 treatment	
of	hypertension	and	heart	failure,	but	also	as	a	strategy	to	control	
hyperkalemia.13	The	kaliuretic	effects	of	these	drugs	may	justify	the	
higher	prevalence	of	RAASi	prescription	 in	patients	prescribed	di‐
uretics,	 since	 the	 increase	of	potassium	excretion	may	 reduce	 the	
potential	of	hyperkalemic	events.
Given	the	high‐level	evidence	 in	support	of	RAASi	use	 in	CKD	
patients,	emphasis	on	ways	to	increase	RAASi	use	is	urgently	war‐
ranted.	In	this	context,	the	much	lower	use	of	RAASi	in	the	United	
States	 and	Brazil	 than	 in	Germany	 and	France	 is	 striking,	 and	 po‐
tentially	 instructive.	Higher	RAASi	use	 in	Germany	may	be	 in	part	
due	to	the	substantially	greater	use	of	oral	bicarbonate	and	potas‐
sium‐binding	 resins	 reported	 in	 this	 analysis.	 Additional	 study	 is	
warranted	to	understand	the	effectiveness	of	such	pharmacological	
interventions	in	the	real‐world	setting,	including	longitudinal	follow‐
up	 in	 CKDopps,	 other	 observational	 studies,	 and	 pragmatic	 inter‐
ventional	studies.	The	analysis	of	the	impact	of	the	new	generation	
of	potassium	binders	(patiromer	and	zirconium,	which	have	a	better	
tolerability	profile	 for	chronic	use)	on	RAASi	prescription,	and	the	
potential	role	of	these	drugs	in	reducing	the	comorbidity	burden	in	
CKD,	remains	to	be	investigated.10
Systems	of	care	likely	also	influence	RAASi	use.	Even	assuming	
US	 nephrologists’	 intentions	 to	 prescribe	 RAASi	 to	 as	many	 CKD	
patients	 as	possible,	disjointed	models	of	 care	may	 limit	 achieving	
this	goal.	In	the	primary	care	clinic,	emergency	room,	or	at	hospital	
discharge,	 decisions	may	 be	made	without	 nephrologist	 consulta‐
tion	to	discontinue	RAASi,	or	to	lower	dose,	in	the	face	of	moderate	
hyperkalemia	 or	 small	 increases	 in	 serum	 creatinine	 levels.	 In	 this	
context,	 better	 coordination	 of	 care	 seems	 essential	 to	 improving	
RAASi	use,	as	well	as	other	care	and	outcomes,	for	these	medically	
challenging	patients.	Solutions	will	be	undoubtedly	complex	and	may	
require	systems	of	accountable	care,	EHRs	that	span	providers,14,15 
and	focused	implementation	science.16
The	cross‐sectional	design	of	the	analysis	has	some	limitations	in	
the	interpretation	of	these	analyses,	since	it	does	not	allow	for	anal‐
ysis	of	 clinical	decision‐making,	particularly	 related	 to	events	 that	
motivated	changes	in	prescription	prior	to	the	inclusion	of	patients	
in	this	study,	for	example,	discontinuation,	changes	from	dual	to	sin‐
gle	 therapy,	 and/or	dose	 reduction	 that	may	occur	 in	 response	 to	
hyperkalemia.	Further	 longitudinal	 investigation	about	 the	change	
in	dose	or	change	in	prescription	regimens	in	response	to	serum	po‐
tassium	levels	is	needed.	Another	limitation	of	the	study	is	that	the	
list	of	medications	captured	in	the	data	analysis	was	limited	due	to	
the	 low	 prevalence	 of	 prescription,	 such	 as	 calcineurin	 inhibitors,	
sulfamethoxazole‐trimethoprim,	 and	 non‐steroidal	 anti‐inflamma‐
tory	agents.
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RAASi	 prescription	 patterns	 in	 CKD	 vary	 by	 country,	 and	 by	
demographic	and	clinical	characteristics.	RAASi	appear	to	be	un‐
derused,	 especially	 in	 the	 United	 States,	 where	 only	 half	 were	
prescribed	 a	RAASi,	 even	 among	patients	with	 strong	 class‐spe‐
cific	 recommendations,	 including	 albuminuria,	 diabetes,	 or	 heart	
failure.	 Higher	 potassium	 levels	 are	 associated	with	 significantly	
higher	RAASi	prescription,	before	and	after	 adjusting	 for	 covari‐
ates,	an	association	which	is	likely	to	reflect	the	hyperkalemic	ef‐
fect	of	RAASi.
In	conclusion,	it	is	plausible	that	RAASi	use	may	be	less	common	
in	patients	at	higher	risk	of	hyperkalemia;	however,	in	cross‐sectional	
analysis,	this	association	may	be	confounded	by:	(a)	RAASi	discontin‐
uation	previous	to	the	period	of	observation;	and	(b)	introduction	of	
anti‐hyperkalemia	measures	(such	as	dose	reduction,	dietary	advice,	
and	potassium	binder	agents)	not	captured	 in	 the	observation	pe‐
riod.	 Therefore,	 prospective	 studies	will	 need	 to	 address	whether	
anti‐hyperkalemia	measures	may	allow	greater	RAASi	use	and	po‐
tentially	improve	renal	and	cardiovascular	outcomes	in	patients	with	
moderate	to	advanced	CKD.
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